Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines

<p>Abstract</p> <p>Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality. However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an international consensus group, including the International Union of Angiology (...

Bibliográfalaš dieđut
Váldodahkki:	Prandoni Paolo
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	BMC 2008-09-01
Ráidu:	Thrombosis Journal
Liŋkkat:	http://www.thrombosisjournal.com/content/6/1/13

Geahča maid

Low-molecular-weight heparins in the treatment of venous thromboembolism
Dahkki: Huisman Menno V, et al.
Almmustuhtton: (2000-08-01)

Modern low-molecular-weight heparins in the prevention and treatment of venous thromboembolic complications in oncourologic patients
Dahkki: N. V. Vorobyev, et al.
Almmustuhtton: (2018-11-01)

Primary prevention of venous thromboembolism with low molecular weight heparins in surgical patients – 2024: Council of Experts resolution
Dahkki: А. S. Petrikov, et al.
Almmustuhtton: (2024-08-01)

Low molecular weight heparin in one or two doses for the initial treatment of venous thromboembolic disease?
Dahkki: Juan Pablo Albornoz, et al.
Almmustuhtton: (2015-12-01)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
Dahkki: Alannah Smrke, et al.
Almmustuhtton: (2017-08-01)

Low-molecular-weight heparin in the prevention of venous thromboembolism among patients with acute intracerebral hemorrhage: A meta-analysis.
Dahkki: Haizheng Li, et al.
Almmustuhtton: (2024-01-01)

Aspirin is as effective as low molecular weight heparins in preventing symptomatic venous thromboembolism following arthroscopic anterior cruciate ligament reconstruction
Dahkki: Hamidreza Yazdi, et al.
Almmustuhtton: (2024-02-01)

Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question
Dahkki: Giuseppe Camporese, et al.
Almmustuhtton: (2023-05-01)

Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question
Dahkki: Giuseppe Camporese, et al.
Almmustuhtton: (2023-05-01)

The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study
Dahkki: Tomasz Olesiński, et al.
Almmustuhtton: (2017-06-01)

Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis
Dahkki: Junjie Liu, et al.
Almmustuhtton: (2023-03-01)

Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight
Dahkki: David Michael Kaylor PharmD, et al.
Almmustuhtton: (2023-02-01)

VENOUS THROMBOEMBOLISM IN RELATION TO OVARIAN HYPERSTIMULATION SYNDROME: AN APPROACH TO DETERMINING THE LOW-MOLECULAR-WEIGHT-HEPARIN DOSES AND ACTIVITY
Dahkki: I. E. Zazerskaya, et al.
Almmustuhtton: (2016-06-01)

Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism
Dahkki: Liew, Ngoh Chin, et al.
Almmustuhtton: (2017)

Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT
Dahkki: Joseph Shalhoub, et al.
Almmustuhtton: (2020-12-01)

Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin
Dahkki: Frank A. Lattuca, et al.
Almmustuhtton: (2023-03-01)

Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery
Dahkki: J Nakase, et al.
Almmustuhtton: (2009-04-01)

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
Dahkki: Yue Wu, et al.
Almmustuhtton: (2024-09-01)

Safety and efficacy of low-molecular-weight heparin in patients with acute venous thromboembolism postthrombolytic therapy as compared to unfractionated heparin: A systematic review and meta-analysis
Dahkki: Eman M. Mansory, et al.
Almmustuhtton: (2024-12-01)

Introduction to the Review Series on venous thromboembolism: emerging issues in pathophysiology and management
Dahkki: Paolo Prandoni
Almmustuhtton: (2024-11-01)

Standard of care and guidelines in prevention and diagnosis of venous thromboembolism: medico-legal implications
Dahkki: Marzia Vassalini, et al.
Almmustuhtton: (2016-06-01)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
Dahkki: Sake J. van der Wall, et al.
Almmustuhtton: (2018-02-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
Dahkki: Sergio Siragusa
Almmustuhtton: (2011-12-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
Dahkki: Sergio Siragusa
Almmustuhtton: (2011-12-01)

Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital
Dahkki: A. S. Kolbin, et al.
Almmustuhtton: (2015-03-01)

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
Dahkki: Kimberly Snow Caroti PharmD, et al.
Almmustuhtton: (2023-08-01)

Risk‐Stratified Venous Thromboembolism Prophylaxis after Total Joint Arthroplasty: Low Molecular Weight Heparins and Sequential Aspirin vs Aggressive Chemoprophylaxis
Dahkki: Hui‐ming Peng, et al.
Almmustuhtton: (2021-02-01)

Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Dahkki: Bryce E Haac, et al.
Almmustuhtton: (2020-01-01)

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients
Dahkki: David R. Anderson, et al.
Almmustuhtton: (2019-12-01)

The Role of the Use of Low Molecular Weight Heparin in the Prevention of Deep Venous Thrombosis after Total Knee Arthroplasty
Dahkki: Auday H. Jasim, et al.
Almmustuhtton: (2011-12-01)

Low-Molecular-Weight Heparin Use in a Case of Noncardiogenic Multifocal Perinatal Thromboembolic Stroke
Dahkki: Matthew A. Saxonhouse, et al.
Almmustuhtton: (2009-01-01)

Low molecular weight heparin.
Dahkki: Gough, S
Almmustuhtton: (1991)

Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with Venous Thromboembolism: Results of a randomized trial (SELECT-D)
Dahkki: Young, A, et al.
Almmustuhtton: (2018)

Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study
Dahkki: Donglin Fu, et al.
Almmustuhtton: (2022-06-01)

Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
Dahkki: Sperati Francesca, et al.
Almmustuhtton: (2008-07-01)

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy
Dahkki: Peimei Zou, et al.
Almmustuhtton: (2019-01-01)

Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis
Dahkki: Tarinee Rungjirajittranon, et al.
Almmustuhtton: (2022-07-01)

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism
Dahkki: Isabel Elías, et al.
Almmustuhtton: (2016-05-01)

Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis
Dahkki: Yifu Zhou, et al.
Almmustuhtton: (2024-05-01)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
Dahkki: Pineo GF, et al.
Almmustuhtton: (2012-04-01)